9 research outputs found
The impact of polypharmacy and drug interactions among the elderly population in Western Sicily, Italy
No full textPolypharmacy, inappropriate medication use and associated factors among brazilian older adults
No full textPrevalence, awareness, treatment, and control of hypertension in older people: results from the population-based KORA-age 1 study
No full textSynergistic effect of renalase and chronic kidney disease on endothelin-1 in patients with coronary artery disease ‒ a cross-sectional study
No full text
Choices for long-term hypertensive control in patients after first-ever hemorrhagic stroke: a nationwide cohort study
No full textCombining angiotensin receptor blockers with chlorthalidone or hydrochlorothiazide – which is the better alternative? A meta-analysis
No full textType 2 Diabetes and Thiazide Diuretics
No full textpeer reviewedPURPOSE OF REVIEW: In patients with prediabetes or type 2 diabetes, the use of thiazides as antihypertensive agents has been challenged because associated metabolic adverse events, including new-onset diabetes. RECENT FINDINGS: These metabolic disturbances are less marked with low-dose thiazides and, in most but not all studies, with thiazide-like diuretics (chlorthalidone, indapamide) than with thiazide-type diuretics (hydrochlorothiazide). In post hoc analyses of subgroups of patients with hypertension and type 2 diabetes, thiazides resulted in a significant reduction in cardiovascular events, all-cause mortality, and hospitalization for heart failure compared to placebo and generally were shown to be non-inferior to other antihypertensive agents. Benefits attributed to thiazide diuretics in terms of cardiovascular event reduction outweigh the risk of worsening glucose control in type 2 diabetes and of new-onset diabetes in non-diabetic patients. Thiazides still play a key role in the management of patients with type 2 diabetes and hypertension
